Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 58.7%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 31,500 shares, a drop of 58.7% from the December 15th total of 76,200 shares. Based on an average trading volume of 787,700 shares, the short-interest ratio is presently 0.0 days.

Astellas Pharma Stock Up 1.6 %

ALPMY opened at $9.70 on Thursday. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26. The company has a market cap of $17.54 billion, a PE ratio of 46.17 and a beta of 0.34. The business has a 50 day moving average price of $10.14 and a two-hundred day moving average price of $11.02. Astellas Pharma has a 52 week low of $9.15 and a 52 week high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.33%. The company had revenue of $3.11 billion during the quarter. As a group, research analysts anticipate that Astellas Pharma will post 0.61 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.